Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Milowsky

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Future Oncology (London, England)|October 2, 2009
Clinical states model for biomarkers in bladder cancerAndrea B Apolo, Matthew Milowsky, Dean F Bajorin
Urologic Oncology|November 3, 2009
Bladder cancer in the elderlyShahrokh F Shariat, Matthew Milowsky, Michael J Droller
Expert Review of Anticancer Therapy|May 15, 2026
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-artCatherine Fahey, Shivani Sud, Anvitha Remella, et al.
The Journal of Urology|February 14, 2007
Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approachAshutosh Tewari, George Divine, Peter Chang, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Clinical Genitourinary Cancer|June 5, 2021
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate CancerDeaglan McHugh, Scott Tagawa, Natalie Moryl, et al.
Urology|January 31, 2021
Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate CancerJamie Michael, Amir H Khandani, Ramsankar Basak, et al.
Contemporary Clinical Trials|February 26, 2022
Non-oncology clinical trial engagement in a nationally representative sample: Identification of motivators and barriersZachary Feuer, Richard S Matulewicz, Ramsankar Basak, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 27, 2022
Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification toolJamie Michael, Nermarie Velazquez, Audrey Renson, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Future Oncology (London, England)|October 2, 2009
Clinical states model for biomarkers in bladder cancerAndrea B Apolo, Matthew Milowsky, Dean F Bajorin
Urologic Oncology|November 3, 2009
Bladder cancer in the elderlyShahrokh F Shariat, Matthew Milowsky, Michael J Droller
Expert Review of Anticancer Therapy|May 15, 2026
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-artCatherine Fahey, Shivani Sud, Anvitha Remella, et al.
The Journal of Urology|February 14, 2007
Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approachAshutosh Tewari, George Divine, Peter Chang, et al.
Seminars in Urologic Oncology|September 7, 2002
The utility of monoclonal antibodies in the imaging of prostate cancerDaniel Yao, Edouard J Trabulsi, Lale Kostakoglu, et al.
Clinical Genitourinary Cancer|June 5, 2021
A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate CancerDeaglan McHugh, Scott Tagawa, Natalie Moryl, et al.
Urology|January 31, 2021
Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate CancerJamie Michael, Amir H Khandani, Ramsankar Basak, et al.
Contemporary Clinical Trials|February 26, 2022
Non-oncology clinical trial engagement in a nationally representative sample: Identification of motivators and barriersZachary Feuer, Richard S Matulewicz, Ramsankar Basak, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 27, 2022
Does histologic subtype impact overall survival in observed T1a kidney cancers compared with competing risks? Implications for biopsy as a risk stratification toolJamie Michael, Nermarie Velazquez, Audrey Renson, et al.
Pageof 2